CAR T-cell Therapy in Republic of Korea — Get 3 Top Clinic Matches with Costs
Medically reviewed by
Fahad Mawlood
How Much Does CAR T-cell therapy Cost in Republic of Korea?
CAR T-cell therapy in the Republic of Korea typically costs from $220,000 to $300,000. The total price depends on the specific drug used, hospital stay duration, and side-effect monitoring. In the United States, patients pay $480,000 on average for this treatment. South Korea offers savings of approximately 46%. Costs generally cover cell collection, genetic engineering, and the infusion process.
- Hospitalization and monitoring: Typically clinical stays last 20 to 21 days for safety.
- Government insurance impact: Insured residents may see out-of-pocket costs drop by over 95%.
- Destination hubs: Most advanced CAR T-cell treatments are concentrated in Seoul medical centers.
- Ancillary medical services: Costs include intensive care monitoring for potential cytokine release syndrome management.
Bookimed Expert Insight: Choosing a high-volume center like Samsung Medical Center provides access to presidential-standard care. This facility serves over 2,000,000 patients annually and holds KOIHA accreditation. The hospital integrates Da Vinci systems and Novalis technology within its Comprehensive Cancer Center. International patients benefit from standardized protocols that match US quality at a significantly lower price point. For those without local insurance, Seoul remains the most cost-effective hub for Kymriah therapy.
| Republic of Korea | Turkey | Austria | |
|---|---|---|---|
| CAR T-cell therapy | ≈ $220,000 | from $200,000 | ≈ $280,000 |
| CAR-T for Pediatric ALL | ≈ $280,000 | ≈ $140,000 | ≈ $290,000 |
| CAR-T for Multiple Myeloma | ≈ $280,000 | ≈ $140,000 | ≈ $330,000 |
| CAR-T for DLBCL | ≈ $280,000 | ≈ $140,000 | ≈ $290,000 |
Your Benefits and Guarantees with Bookimed
Transparent Prices & Flexible Installments
No hidden fees – just official clinic prices. Pay at the clinic for CAR T-cell therapy upon arrival and use a flexible installment plan if needed.
Verified Clinics & Doctors Only
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in CAR T-cell therapy and have the necessary licenses to serve international patients worldwide.
Free 24/7 Assistance
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your CAR T-cell therapy journey.
Your personal Bookimed medical coordinator
- Supports you at every stage
- Helps choose the right clinic and doctor
- Ensures quick and convenient access to information
Discover the Best CAR T-cell therapy Clinics in Republic of Korea: 1 Verified Option and Prices
CAR T-cell therapy Overview in Republic of Korea
Day 1
- Arrive at the airport.
- Enjoy the provided transfer to the clinic.
- Meet your language assistant if needed.
Day 2 - Day 3
- Undergo medical examination by a specialist.
- Receive a consultation with a hematologist.
- Undertake necessary tests (blood test, biopsy).
- If required, pre-operative procedures will be performed.
Day 4
- Start the CAR T-cell therapy process.
- Your T-cells will be collected and modified.
- This process lasts for about 2-3 hours.
- Local anesthesia is typically used.
Day 5 - Day 12
- Your modified T-cells are grown in the lab.
- No direct actions are required from you.
Day 13
- Receive your modified T-cells back via infusion.
- The infusion process lasts for about 1 hour.
Day 14 - Day 20
- Stay in the clinic for observation.
- Monitor your response to the therapy.
Week 3 - Week 4
- Continue to monitor your health condition.
- Consult with medical professionals regularly.
Week 5 onwards
- Rehabilitation begins.
- Resume work and moderate activities after 6 weeks.
- Return to intense activities like sports after 8 weeks.
- Expect to see the final result after 3 months.
Please note that each case is individual. This timeline may vary based on your personal health condition and the specifics of your treatment plan.
- Bookimed deposit: $200 or €200.
- Clinic deposit: Pay a set percentage in advance.
Our Doctors
View all Doctors
Keun Chil Park
Dr. Keun Chil Park leads the Division of Hematology-Oncology at Samsung Medical Center in Seoul. He specializes in treating lung, esophageal, and head and neck cancers. Dr. Park earned his medical degree from Seoul National University College of Medicine.
- Member of the American Society of Clinical Oncology (ASCO).
- Member of the European Society of Medical Oncology (ESMO).
- Affiliated with the International Association for the Study of Lung Cancer.
- Works at a hospital ranked among the world’s best by Newsweek.
Related Articles
CAR T-Cell Therapy Cost Effectiveness
Written by Anna Leonova
Share this content
Video Stories from Bookimed Patients
Anna Leonova
FAQ about CAR T-cell therapy in Republic of Korea
Which centers in South Korea are qualified to provide CAR T-cell therapy?
Qualified centers in South Korea must receive Ministry of Food and Drug Safety approval to administer CAR T-cell therapy. Primary authorized facilities include Samsung Medical Center, Seoul National University Hospital, and Seoul St. Mary Hospital. These institutions manage commercial products like Kymriah for lymphoma and leukemia patients.
- Samsung Medical Center: Established the first dedicated CAR T-Cell Center in South Korea in 2021.
- Seoul National University: First hospital authorized to produce CAR T-cells internally for pediatric leukemia cases.
- Seoul St. Mary: Features an on-site GMP cell processing center for advanced immune cell research.
- Regulatory compliance: Facilities must strictly follow the Advanced Biological Product Safety Act for certification.
Bookimed Expert Insight: Samsung Medical Center serves over 2,000,000 patients annually and maintains a presidential-tier infrastructure. This high volume translates to significant experience in complex oncology. Their early adoption of a dedicated center makes them a leader in managing cytokine release syndrome. This specialized care is vital for patient safety during the aggressive CAR T-cell infusion phase.
Patient Consensus: Patients emphasize the need for official verification. They recommend contacting oncology departments directly to confirm current KFDA approval status for specific therapies. Many suggest budgeting over $300,000 and planning for a 6-week stay.
What CAR T-cell products are commercially approved in the Republic of Korea?
South Korea's Ministry of Food and Drug Safety has approved four major CAR T-cell therapies: Kymriah (tisagenlecleucel), Yescarta (axicabtagene ciloleucel), Carvykti (ciltacabtagene autoleucel), and Rimqarto (anbalcabtagene autoleucel). These products treat specific lymphomas and multiple myeloma. Administration occurs at specialized centers like Samsung Medical Center.
- Kymriah (Novartis): Approved in 2021 for pediatric ALL and adult DLBCL.
- Yescarta (Gilead): Treats relapsed large B-cell lymphoma and primary mediastinal lymphoma.
- Carvykti (Janssen): Indicated for adult patients with relapsed or refractory multiple myeloma.
- Rimqarto (Curocell): The first homegrown Korean CAR T-cell drug targeting CD19.
Bookimed Expert Insight: While approvals are increasing, manufacturing logistics remain a significant bottleneck. Data shows patients often wait over 6 months for imported products. Top centers like Samsung Medical Center manage these timelines better due to high patient volumes. They serve over 2,000,000 patients annually and have established apheresis protocols.
Patient Consensus: Patients emphasize the need to verify hospital capabilities early. They often report that insurance coverage lags behind regulatory approval, making out-of-pocket costs a major concern.
Which hematologic malignancies are reimbursed for CAR T-cell therapy under Korea’s National Health Insurance?
South Korea National Health Insurance covers CAR T-cell therapy primarily for relapsed or refractory diffuse large B-cell lymphoma and pediatric B-cell acute lymphoblastic leukemia. Coverage usually applies starting from third-line treatment under strict National Health Insurance Service guidelines at accredited medical centers.
- Large B-cell lymphoma: Reimbursed as third-line therapy for adult patients with relapsed or refractory disease.
- Acute lymphoblastic leukemia: Covered for pediatric and young adult patients up to 25 years old.
- Mantle cell lymphoma: Benefits expanded in 2022 to include this specific hematologic malignancy.
- Follicular lymphoma: Approved for clinical use but reimbursement varies significantly by individual case.
Bookimed Expert Insight: Samsung Medical Center serves over 2,000,000 patients annually and holds KOIHA accreditation for safety. Their high volume suggests they manage the complex National Health Insurance reimbursement and hospital-level approvals efficiently. Patients should verify their specific malignancy against the latest risk-sharing agreements at such high-capacity centers.
Patient Consensus: Patients report that while pediatric leukemia coverage is reliable, many adults with multiple myeloma face private costs. Most advise preparing for a 10% to 20% copay even when insurance approves the treatment.
What ongoing CAR T-cell clinical trials are recruiting in South Korea?
South Korea actively recruits for CAR T-cell clinical trials targeting lymphoma, leukemia, and liver cancer. Prominent studies include the ALPHA3 trial for B-cell lymphoma and the EU307 phase 1 trial for hepatocellular carcinoma. Enrollment centers include Samsung Medical Center and Seoul National University Hospital.
- Hematologic malignancies: The ALPHA3 trial evaluates first-line consolidation for large B-cell lymphoma.
- Leukemia research: Anbal-cel phase 2 trials investigate treatments for adult acute lymphoblastic leukemia.
- Solid tumors: EU307 phase 1 tests anti-GPC3 therapy for advanced liver cancer patients.
- Autoimmune applications: Clinics recruit for low-dose CAR-T trials treating refractory Systemic Lupus Erythematosus.
Bookimed Expert Insight: While many global trials use ClinicalTrials.gov, South Korean centers often prioritize the local CRIS registry. Samsung Medical Center, which serves over 2,000,000 patients annually, frequently operates internal trial pipelines. Checking their specific Cancer Center listings usually reveals more active slots than international databases.
Patient Consensus: Many find that trial information is mainly available in Korean. Direct contact with tier-1 hospital international departments is more effective than searching public online listings.